{"links":{"html":"https://www.erudio.com/reports/oligoma-nct04495309","json":"https://www.erudio.com/reports/oligoma-nct04495309.json","markdown":"https://www.erudio.com/reports/oligoma-nct04495309.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"oligoma-04495309"}},"request":"https://www.erudio.com/contact?report=oligoma-04495309"},"offer":{"cited_commentary_sources":24,"verified_hcp_statements":238,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1250,"identity_verified_people":41,"optional":true,"price_per_verified_person_usd":15,"price_usd":615,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"oligoma-nct04495309"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=oligoma-04495309","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/oligoma-nct04495309","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_rule":"Standard: 151–300 verified statements","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-28T14:01:37.155185Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":15,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":12,"title":"Primary endpoint: First co-primary outcome measure is progression-free survival (PFS)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":2,"title":"Primary endpoint: Second co-primary outcome measure is quality of life"},{"claim_count":4,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":3,"title":"Secondary endpoints"},{"claim_count":16,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":12,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":6,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":6,"title":"Safety and tolerability"},{"claim_count":12,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":23,"coverage":"discussed","id":"A1","source_count":5,"title":"Initial versus induced oligometastases and evolving BR002 interpretations"},{"claim_count":7,"coverage":"discussed","id":"A2","source_count":3,"title":"Imaging sensitivity, eligibility and German PET access"},{"claim_count":17,"coverage":"discussed","id":"A3","source_count":5,"title":"CTC and ctDNA selection: predictive hypotheses versus subgroup skepticism"},{"claim_count":34,"coverage":"discussed","id":"A4","source_count":4,"title":"Treated-area progression, dose and cross-study local-control comparisons"},{"claim_count":20,"coverage":"discussed","id":"A5","source_count":1,"title":"Radiation response, pathological viability and clinical failure"},{"claim_count":55,"coverage":"discussed","id":"A6","source_count":8,"title":"Evidence thresholds, replication and histology-aware pooling"},{"claim_count":22,"coverage":"discussed","id":"A7","source_count":4,"title":"Systemic control, longitudinal disease pace and repeat SABR"},{"claim_count":12,"coverage":"discussed","id":"A8","source_count":2,"title":"Guideline timing, interpretation and specialty involvement"}],"counts":{"cited_sources":25,"claims_by_expression_type":{"comparison":30,"experience":9,"interpretation":68,"opinion":62,"primary_context":3,"question":21,"restatement":26,"uncertainty":15,"unspecified":4},"claims_by_kind":{"publication_statement":17,"source_observation":221},"clinician_statements":104,"evidence_units":239,"findings":11,"organisational_accounts":3,"people_cited":42,"people_identity_verified":41,"people_total":44,"screened_sources":33,"verified_claims":238},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":2,"views":8},"has_counterview":true,"limitations":2,"links":{"context":0,"support":12},"ma_question":true,"named_voices":8,"passages":10,"sources":8,"sources_by_kind":{"commentary":8}},"title":"Routine use versus trial-only care remains the consequential divide"},{"id":"F2","structure":{"claims":24,"claims_by_group":{"comparisons":4,"experience":0,"questions":3,"restated":5,"views":12},"has_counterview":true,"limitations":3,"links":{"context":3,"support":25},"ma_question":true,"named_voices":10,"passages":26,"sources":6,"sources_by_kind":{"commentary":4,"media":1,"publication":1}},"title":"Selection and earlier consolidation are proposed, not demonstrated, effect modifiers"},{"id":"F3","structure":{"claims":30,"claims_by_group":{"comparisons":4,"experience":1,"questions":6,"restated":7,"views":12},"has_counterview":true,"limitations":3,"links":{"context":2,"support":33},"ma_question":true,"named_voices":8,"passages":27,"sources":6,"sources_by_kind":{"commentary":6}},"title":"BR002 population and PET explanations were corrected or left open"},{"id":"F4","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":4,"views":13},"has_counterview":true,"limitations":3,"links":{"context":2,"support":18},"ma_question":true,"named_voices":11,"passages":18,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Biomarker enthusiasm is exploratory and contested"},{"id":"F5","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":2,"questions":1,"restated":1,"views":13},"has_counterview":true,"limitations":3,"links":{"context":1,"support":23},"ma_question":true,"named_voices":5,"passages":15,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Systemic effectiveness and changing disease pace qualify the local-treatment question"},{"id":"F6","structure":{"claims":40,"claims_by_group":{"comparisons":11,"experience":0,"questions":12,"restated":5,"views":12},"has_counterview":true,"limitations":3,"links":{"context":1,"support":40},"ma_question":true,"named_voices":10,"passages":35,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Local-event definitions matter, but better local control would not automatically yield PFS benefit"},{"id":"F7","structure":{"claims":20,"claims_by_group":{"comparisons":1,"experience":1,"questions":6,"restated":0,"views":12},"has_counterview":true,"limitations":3,"links":{"context":2,"support":22},"ma_question":true,"named_voices":7,"passages":22,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Radioresistance remains a disputed hypothesis"},{"id":"F8","structure":{"claims":54,"claims_by_group":{"comparisons":6,"experience":1,"questions":6,"restated":4,"views":37},"has_counterview":true,"limitations":5,"links":{"context":4,"support":57},"ma_question":true,"named_voices":13,"passages":59,"sources":8,"sources_by_kind":{"commentary":6,"media":1,"publication":1}},"title":"The evidence dispute concerns inference, replication and cross-histology borrowing"},{"id":"F9","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":9},"has_counterview":true,"limitations":3,"links":{"context":0,"support":14},"ma_question":true,"named_voices":6,"passages":10,"sources":8,"sources_by_kind":{"commentary":7,"publication":1}},"title":"Progression delay, quality of life and rare cure are different objectives"},{"id":"F10","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":4,"questions":0,"restated":2,"views":4},"has_counterview":true,"limitations":2,"links":{"context":1,"support":11},"ma_question":true,"named_voices":8,"passages":11,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Equipoise and communication constrain evidence generation"},{"id":"F11","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":0,"views":8},"has_counterview":true,"limitations":2,"links":{"context":1,"support":13},"ma_question":true,"named_voices":6,"passages":13,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Guideline omission has a timing explanation, not a proven dismissal"}],"medical_affairs_question":"Which patients, if any, should be considered for SBRT now, and what additional evidence would change that threshold?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Routine use versus trial-only care remains the consequential divide"},{"id":"section-2","level":2,"title":"Selection and earlier consolidation are proposed, not demonstrated, effect modifiers"},{"id":"section-3","level":2,"title":"BR002 population and PET explanations were corrected or left open"},{"id":"section-4","level":2,"title":"Biomarker enthusiasm is exploratory and contested"},{"id":"section-5","level":2,"title":"Systemic effectiveness and changing disease pace qualify the local-treatment question"},{"id":"section-6","level":2,"title":"Local-event definitions matter, but better local control would not automatically yield PFS benefit"},{"id":"section-7","level":2,"title":"Radioresistance remains a disputed hypothesis"},{"id":"section-8","level":2,"title":"The evidence dispute concerns inference, replication and cross-histology borrowing"},{"id":"section-9","level":2,"title":"Progression delay, quality of life and rare cure are different objectives"},{"id":"section-10","level":2,"title":"Equipoise and communication constrain evidence generation"},{"id":"section-11","level":2,"title":"Guideline omission has a timing explanation, not a proven dismissal"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, na","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":2},{"id":"F6","shared_claims":3},{"id":"F8","shared_claims":3},{"id":"F9","shared_claims":3},{"id":"F10","shared_claims":1}],"id":"T1","label":"Primary endpoint: First co-primary outcome measure is progression-free survival (PFS)"},{"findings":[{"id":"F9","shared_claims":2}],"id":"T2","label":"Primary endpoint: Second co-primary outcome measure is quality of life"},{"findings":[{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":1},{"id":"F9","shared_claims":4}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":14},{"id":"F3","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":3},{"id":"F5","shared_claims":3},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":2},{"id":"F11","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":2}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":2},{"id":"F6","shared_claims":2},{"id":"F10","shared_claims":7}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-28T14:01:37.155185Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-28T14:27:43Z","record_hash":"b37cdb1de55ab9fa291f193ef96bbca65a03481cd752f76ae9a5a3b3bf902d89","release_hash":"a6cef63dfa2fc12476779e29dd691945c1ea4028fec0cade6d60c79618ae2ceb","report_id":"erudio-nct04495309","run_id":"19aedb24-4133-4610-ab74-97113ca5651e","schema_version":"5.0","slug":"oligoma-04495309","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"OLIGOMA asks whether adding radiotherapy to systemic therapy can delay progression without worsening quality of life in oligometastatic breast cancer. Clinicians in the sources reviewed for this edition differ over routine local treatment versus trial-only care. Enthusiasm for progression delay coexists with scrutiny of patient selection and evidence thresholds. The clinical role of SBRT and requirements for further confirmation remain unresolved.","meta_description":"33 sources screened · 238 verified statements (104 from clinicians verified by NPI or staff page) from 25 sources · 11 findings. Updated Oct 28, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-df149880d9fde854c57b"],"id":"F2","paraphrase":"A Bluesky contributor asked which breast cancer subtypes were represented among OLIGOMA participants.","publication_caveats":{"reason":"Publication caveats are not stated for this source.","status":"not_set"},"source_channel":"bluesky_thread","source_date":"2026-05-17","title":"Selection and earlier consolidation are proposed, not demonstrated, effect modifiers"},{"cited_claim_ids":["claim-3cbd619aabd449dcd38a"],"id":"F6","paraphrase":"An X-thread contributor asked how to explain the differences between BR002 and OLIGOMA.","publication_caveats":["The discussion includes posts dated 11 and 21 October 2026; the date of this individual question is not specified."],"source_channel":"x_thread","source_date":{"reason":"The exact publication date of this question is not stated.","status":"unavailable"},"title":"Local-event definitions matter, but better local control would not automatically yield PFS benefit"}]},"publication":{"approved_at":"2026-10-28T14:27:43Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":33},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","The source search did not run to completion, so some matching discussion may be missing.","1 matching source (1 X thread) could not be read and is not included.","Not yet captured in this edition: a view on disease differences and imaging limitations when interpreting metastasis-directed therapy evidence across cancers.","Not yet captured in this edition: a view on investigating and quantifying potential survival or cure benefits of metastases-directed treatment.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","35 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","Public posts and one historical interview do not establish how widely any position is shared. Reposts and repeated quotations are not additional independent opinions.","The reviewed OLIGOMA outcomes discussion is conference-based. No primary outcomes publication is available here, and comments differ slightly in reported medians and confidence-limit rounding. These differences should not be silently combined into one verified results account.","Speakers describe a small study stopped early for slow recruitment and a largely low-burden, earlier-line population. Enthusiasm should not be generalized to every patient eligible under the broader protocol.","Short-term quality-of-life reports and general confidence in oligoSBRT safety do not establish formal quality-of-life non-inferiority, comprehensive graded toxicity, late effects or patient-satisfaction outcomes.","The comments do not independently settle BR002's disputed initial-burden interpretation, characterize all treated-area events, or validate CTC/ctDNA selection thresholds. These remain open questions rather than established explanations for trial differences.","A follow-up qualification in the survival-or-cure discussion was not available in full, limiting completeness of that exchange.","Several contributors' clinical roles are not established in the reviewed material, and account-level or organizational commentary cannot be assumed to represent an identifiable individual clinician."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":22,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":24,"context":1},"count":25,"evidence_window":{"end":"2026-10-21","start":"2021-04-10"},"retrieval_snapshot":"2026-10-28T13:03:04.802421Z","timeline":[{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W15"},{"count":1,"week":"2022-W19"},{"count":1,"week":"2022-W23"},{"count":1,"week":"2023-W20"},{"count":7,"week":"2026-W20"},{"count":8,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W38"},{"count":5,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":2,"week":"2026-W43"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT04495309:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04495309:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:33912695","quote_policy":"no_derivatives"},{"id":"mcp:bluesky_thread:plc-2ofweipvqenfiq4v3ghh6w66-3mm4hmgap7s2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-3jqvfiysnaxmh5cekxczgqow-3msuhaf66b22z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3mm4dmytwyo2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-x7czo2gffuwduemimxytkzuo-3mm2t7ab5s22i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mm2ht3q4xk22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1380888753305223178:c39df54b-005c-4ca5-8cf7-589752fb88bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1523638213524410369:c1a0ab90-7192-475f-aa45-08960a36a3ae","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1534372103675338752:f9f41dd3-661d-4e9b-918b-bd2f243b0a43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055990735011221831:97745a2f-627b-40e9-b4ca-90b9fb403bc1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055992725896306759:2e1f0a39-7877-4f7c-9116-14f797b653e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2055997750420873308:3f7461fd-a0c7-497c-9590-f0a4e46cca9b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056004360115462277:8c4fb144-1cc4-4706-931e-2093a2cad366","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056007526802510022:e2f06ec1-d2b3-451e-83a5-1477dd5a94f1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056054933368004746:6f522aac-e8c6-4b77-b152-d4ce33d9bf14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056120095965946156:11f07b0f-0da3-4dc1-9932-8313404dd5fd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056137843735482788:c90fa8ce-12d7-4d26-9361-249d772cdea7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056201873083019700:987c39a6-d6ac-40fc-95be-eb9dad37536a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056244368088916303:d345c85a-3f4d-4678-a18d-0231d63afe41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056312670521790673:2a202a74-5cc9-4183-869e-cbad8d76365b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056404632025416103:a54c49ea-61e5-4d79-8278-c39d9e50c4f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056455791880929645:4235863b-81ed-4e86-a1ac-fd1ecf02e594","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056786356911685792:b6c0c941-c731-4e5c-8fc8-1f273ca1ace1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060492100714614838:f8c53519-eda8-4f3d-8336-160a49e5dd3a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087418854536274065:80c8a76f-9230-468f-8bfb-ae9b0e124887","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100892237823394052:70947685-1ae5-4d11-935f-5e81f7d18073","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104987917529563370:6c30cc02-6be9-43ff-8c39-f96e58e74d96","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107947162520736208:b73a02cd-b8fb-4256-90d5-ad217d5b5bac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108001797512065108:6200665a-2b35-47ab-8f8e-08d0718f4457","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109106546684932244:9e288824-9fe1-4fbd-ad5c-6f4a54ece6c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110714503729910163:ddf77d21-4535-454a-a561-b59c4eede788","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112247987988496520:2defd722-e0a8-4cae-99ea-abf2b2c2be32","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115187078866899311:5c2b1dc3-fe1c-46a8-85ed-72e0d5a477fb","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:K2PyBEzF3qs","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":5,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":27,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":33},"count":33,"evidence_window":{"end":"2026-10-27","start":"2021-04-10"},"retrieval_snapshot":"2026-10-28T13:03:04.802421Z","timeline":[{"count":1,"week":"2021-W14"},{"count":1,"week":"2021-W15"},{"count":1,"week":"2022-W19"},{"count":1,"week":"2022-W23"},{"count":1,"week":"2023-W20"},{"count":10,"week":"2026-W20"},{"count":10,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W33"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W40"},{"count":5,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":2,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":{"reason":"Registry lists no drug interventions.","status":"not_applicable"},"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"OLIGOMA","aliases":["OLIGOMA","Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer","Effectiveness and Tolerability of Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer: A Randomized Controlled Multinational and Multicenter Clinical Trial"],"brief_title":"Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":87,"type":"ACTUAL"},"interventions":[{"name":"Metastases-directed Radiotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"}],"nct_id":"NCT04495309","official_title":"Effectiveness and Tolerability of Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer: A Randomized Controlled Multinational and Multicenter Clinical Trial","overall_status":"COMPLETED","phase":["NA"],"primary_completion_date":{"date":"2025-06-03","type":"ACTUAL"},"primary_endpoints":[{"description":"Co-primary progression-free survival (PFS) according to Response Evaluation Criteria In Solid Tumors (RECIST)","measure":"First co-primary outcome measure is progression-free survival (PFS)","timeFrame":"at least 12 months after randomization"},{"description":"Co-primary quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer patients with 30 items (QLQ-C30) sum score","measure":"Second co-primary outcome measure is quality of life","timeFrame":"12 weeks after randomization"}],"registry_last_updated":"2026-02-27","registry_url":"https://clinicaltrials.gov/study/NCT04495309","short_name":"OLIGOMA","short_name_basis":"registry_acronym","sponsor":"University Hospital Schleswig-Holstein","start_date":{"date":"2021-03-05","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, na","study_ids":[{"id":"ARO-2015-1","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}